FERMT2 and breast cancer: These results were replicated in murine 4T1 BC model, where CRISPR/Cas9-mediated knockout of Kindlin-2 (Fig. 3C), also resulted in ~10-fold decrease (p < 0.01) in the number of lung metastasis foci in mice implanted with the Kindin-2-deficient 4T1 cells, compared to the control cells (Fig. 3D,E).